Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertil Jonsson

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Lakartidningen|October 27, 2010
[Hazards with mobile phones during driving. Time for a more stringent legislation and smarter technology according to a pilot study]Bertil Jonsson
Traffic Injury Prevention|April 7, 2011
Hand position on steering wheel during drivingBertil Jonsson
Nature Reviews. Clinical Oncology|February 22, 2012
Hurdles in anticancer drug development from a regulatory perspectiveBertil Jonsson, Jonas Bergh
Lakartidningen|May 19, 2010
[Targeted drugs a chance for a better cure]Jonas Bergh, Bertil Jonsson
Lakartidningen|February 8, 2011
[Medical Product Agency about Multiferon: positive benefit-risk relation]Bertil Jonsson, Hans Melander
American Journal of Hematology|September 19, 2012
Platelet response as the basis for approval in chronic immune (idiopathic) thrombocytopenic purpura (ITP): a regulatory perspectiveFrancesco Pignatti, Beatriz Flores, Bertil Jonsson
Traffic Injury Prevention|December 6, 2008
Backset-stationary and during car drivingBertil Jonsson, Hans Stenlund, Ulf Björnstig
European Journal of Cancer (Oxford, England : 1990)|June 7, 2011
Is it time to abandon complete blinded independent central radiological evaluation of progression in registration trials?Francesco Pignatti, Rob Hemmings, Bertil Jonsson
Molecular Oncology|December 8, 2014
Assessment of benefits and risks in development of targeted therapies for cancer--The view of regulatory authoritiesFrancesco Pignatti, Bertil Jonsson, Gideon Blumenthal, et al.
Chinese Clinical Oncology|April 6, 2015
The changing world of cancer drug development: the regulatory bodies' perspectiveIordanis Gravanis, Camille Vleminckx, Bertil Jonsson, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Lakartidningen|October 27, 2010
[Hazards with mobile phones during driving. Time for a more stringent legislation and smarter technology according to a pilot study]Bertil Jonsson
Traffic Injury Prevention|April 7, 2011
Hand position on steering wheel during drivingBertil Jonsson
Nature Reviews. Clinical Oncology|February 22, 2012
Hurdles in anticancer drug development from a regulatory perspectiveBertil Jonsson, Jonas Bergh
Lakartidningen|May 19, 2010
[Targeted drugs a chance for a better cure]Jonas Bergh, Bertil Jonsson
Lakartidningen|February 8, 2011
[Medical Product Agency about Multiferon: positive benefit-risk relation]Bertil Jonsson, Hans Melander
American Journal of Hematology|September 19, 2012
Platelet response as the basis for approval in chronic immune (idiopathic) thrombocytopenic purpura (ITP): a regulatory perspectiveFrancesco Pignatti, Beatriz Flores, Bertil Jonsson
Traffic Injury Prevention|December 6, 2008
Backset-stationary and during car drivingBertil Jonsson, Hans Stenlund, Ulf Björnstig
European Journal of Cancer (Oxford, England : 1990)|June 7, 2011
Is it time to abandon complete blinded independent central radiological evaluation of progression in registration trials?Francesco Pignatti, Rob Hemmings, Bertil Jonsson
Molecular Oncology|December 8, 2014
Assessment of benefits and risks in development of targeted therapies for cancer--The view of regulatory authoritiesFrancesco Pignatti, Bertil Jonsson, Gideon Blumenthal, et al.
Chinese Clinical Oncology|April 6, 2015
The changing world of cancer drug development: the regulatory bodies' perspectiveIordanis Gravanis, Camille Vleminckx, Bertil Jonsson, et al.
Pageof 2